Impact of Gut Dysbiosis on the Risk of Non-Small-Cell Lung Cancer

被引:8
|
作者
Wei, Yu-Feng [1 ,2 ,3 ]
Huang, Ming-Shyan [3 ]
Huang, Cheng-Hsieh [4 ,5 ]
Yeh, Yao-Tsung [5 ,6 ]
Hung, Chih-Hsin [1 ]
机构
[1] I Shou Univ, Inst Biotechnol & Chem Engn, Kaohsiung 84001, Taiwan
[2] I Shou Univ, Coll Med, Sch Med Int Students, Kaohsiung 82445, Taiwan
[3] E Da Canc Hosp, Dept Internal Med, Kaohsiung 82445, Taiwan
[4] Kaohsiung Med Univ, PhD Program Environm & Occupat Med, Kaohsiung 80708, Taiwan
[5] Fooyin Univ, Aging & Dis Prevent Res Ctr, Kaohsiung 83102, Taiwan
[6] Fooyin Univ, Dept Med Lab Sci & Biotechnol, Kaohsiung 83102, Taiwan
关键词
dysbiosis; gut microbiota; microbiome; non-small-cell lung cancer; MICROBIOTA; IDENTIFICATION; HSP90-BETA; DIVERSITY; BIOMARKER; DISEASE; PROTEIN; IMMUNE; COHORT; COPD;
D O I
10.3390/ijerph192315991
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Background: The imbalance of gut microbiota, dysbiosis, is associated with various malignant diseases. This study aimed to identify the characteristics of gut microbiota in age-matched treatment-naive non-small-cell lung cancer (NSCLC) patients and healthy individuals to investigate possible gut-microbe-related pathways involved in the development of NSCLC. Methods: We enrolled 34 age-matched NSCLC patients and 268 healthy individuals. Hypervariable V3-V4 amplicons of 16S rRNA in freshly collected fecal samples were sequenced. Diversity, microbial composition, functional pathways, smoking history, and gut-microbe-related comorbidities were analyzed to assess the factors associated with the risk of NSCLC. Results: Microbial alpha diversity was decreased in the patients with NSCLC, and beta diversity was significantly different between the patients and controls (p < 0.001). After adjustments for sex, smoking history, hypertension, diabetes mellitus, chronic obstructive pulmonary disease, and 11 abundant microbes with significant differences between the patients and controls, the enrichment of Anaerotruncus spp. and Bacteroides caccae was associated with an increased risk of NSCLC (p = 0.003 and 0.007, respectively). The areas under receiver operating characteristic curves were 71.4% and 66.9% for Anaerotruncus spp. and Bacteroides caccae, respectively (both p < 0.001). Furthermore, the abundance of Bacteroides caccae was positively correlated with steroid hormone biosynthesis (p < 0.001), N-glycan biosynthesis (p = 0.023), glycosaminoglycan degradation (p < 0.001), lipoic acid metabolism (p = 0.039), peroxisome (p < 0.001), and apoptosis (p < 0.001), but inversely related to glycerolipid metabolism (p < 0.001). Anaerotruncus spp. was positively associated with decreased biosynthesis of ansamycin only (p = 0.001). No overlapping signaling pathways were modulated by Bacteroides caccae or Anaerotruncus spp. Conclusions: Our results revealed that fecal Anaerotruncus spp. and Bacteroides caccae were abundant and may be associated with the risk of NSCLC regardless of sex, smoking history, and gut-microbe-related comorbidities. Further investigations on the mechanism underlying the potential association between gut dysbiosis and the development of NSCLC are warranted.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Adagrasib in Non-Small-Cell Lung Cancer
    Kotecha, Rupesh
    Sahgal, Arjun
    Mehta, Minesh P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (13): : 1238 - 1239
  • [22] Non-small-cell lung cancer in the elderly
    Meriggi, F
    Zaniboni, A
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 57 (02) : 183 - 190
  • [23] Cetuximab in non-small-cell lung cancer
    Carillio, Guido
    Montanino, Agnese
    Costanzo, Raffaele
    Sandomenico, Claudia
    Piccirillo, Maria Carmela
    Di Maio, Massimo
    Daniele, Gennaro
    Giordano, Pasqualina
    Bryce, Jane
    Normanno, Nicola
    Rocco, Gaetano
    Perrone, Francesco
    Morabito, Alessandro
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (02) : 163 - 175
  • [24] Immunotherapy for non-small-cell lung cancer
    Thomas, Anish
    Jakopovic, Marko
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (08) : 1061 - 1064
  • [25] Staging of Non-Small-Cell Lung Cancer
    Akhurst, Tim
    [J]. PET CLINICS, 2018, 13 (01) : 1 - +
  • [26] LncRNAs in Non-Small-Cell Lung Cancer
    Ginn, Lucy
    Shi, Lei
    La Montagna, Manuela
    Garofalo, Michela
    [J]. NON-CODING RNA, 2020, 6 (03)
  • [27] Chemotherapy for non-small-cell lung cancer
    Satoh, H
    Sekizawa, K
    [J]. LANCET, 2001, 358 (9289): : 1270 - 1271
  • [28] Ifosfamide in non-small-cell lung cancer
    Rosell, R
    Martin, C
    Balaña, C
    [J]. ANNALS OF ONCOLOGY, 1999, 10 : 25 - 28
  • [29] Cetuximab in non-small-cell lung cancer
    Pirker, Robert
    Filipits, Martin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2012, 1 (01) : 54 - 60
  • [30] Cancer vaccines for non-small-cell lung cancer
    Palma, M.
    Choudhury, A.
    Mellstedt, H.
    [J]. MINERVA CHIRURGICA, 2009, 64 (06) : 643 - 653